Anthrax - Pipeline Insight, 2024

This “Anthrax - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anthrax Understanding

Anthrax: Overview

Anthrax is caused by the gram-positive Bacillus anthracis, which are toxin-producing, encapsulated, facultative anaerobic organisms. Anthrax, an often fatal disease of animals, is transmitted to humans by contact with infected animals or their products. In humans, infection is typically acquired through the skin. Inhalation infection is less common; oropharyngeal, meningeal, and gastrointestinal infections are rare. For inhalation and gastrointestinal infections, nonspecific local symptoms are typically followed in several days by severe systemic illness, shock, and often death. Empiric treatment is with ciprofloxacin, levofloxacin, moxifloxacin, or doxycycline.

Anthrax - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines. The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.

Anthrax Emerging Drugs Chapters

This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anthrax Emerging Drugs

GC1109: GC Pharma GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder. This vaccine is obtained by cultivating and purifying genetically engineered Bacillus brevis. In the phases 1 and 2 of clinical trials, GC1109 has displayed an excellent safety profile and dose-dependent immunogenicity. Currently, it is in phase II stage of development.

AV7909: Emergent Bio Solutions The vaccine candidate AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. AV7909 is comprised of Anthrax Vaccine Adsorbed (AVA) in combination with an adjuvant. The vaccine is currently in phase III stage ofdevelopment.

Anthrax: Therapeutic Assessment

This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anthrax

There are approx. 10+ key companies which are developing the therapies for Anthrax. The companies which have their Anthrax drug candidates in the most advanced stage, i.e. phase III include, Emergent BioSolutions.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anthrax pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anthrax: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anthrax therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anthrax drugs.

Anthrax Report Insights

• Anthrax Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anthrax Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anthrax drugs?
• How many Anthrax drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anthrax?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anthrax therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anthrax and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GC Pharma
• Emergent BioSolutions
• Blue WillowBiologics
• Paratek Pharmaceuticals
• Altimmune
• Greffex
• Planet Biotechnology
• Integrated BioTherapeutics
• DEINOVE
• Hawaii Biotech
• VLP Biotech
• Aphios Corporation
• Enesi

Key Products

• GC1109
• AV7909
• BW 1010
• Omadacycline
• r PA102
• NasoShield

Research programme: DNA vaccines- PBI 220

• Ba ISTAb
• DNV3837

This product will be delivered within 2 business days.